In the context of hemophilia, adeno-associated virus (AAV)—mediated gene therapy has achieved landmark success with therapies such as etranacogene dezaparvovec and valctocogene roxaparvovec delivering durable expression of factor IX and VIII, respectively and significantly reducing bleeding episodes [12, 13]. Here, F9 is linked to hemophilia.